Literature DB >> 23578679

Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years.

R Zivadinov1, N Bergsland, O Dolezal, S Hussein, Z Seidl, M G Dwyer, M Vaneckova, J Krasensky, J A Potts, T Kalincik, E Havrdová, D Horáková.   

Abstract

BACKGROUND AND
PURPOSE: Pathologic changes in GM have an important role in MS. We investigated the association between SDGM and cortical volume changes and disability progression in early RRMS.
MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method.
RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P < .001), thalamus (P = .006), and total SDGM (P = .0095) volume.
CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23578679      PMCID: PMC7965442          DOI: 10.3174/ajnr.A3503

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  43 in total

1.  Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.

Authors:  Stephen M Smith; Yongyue Zhang; Mark Jenkinson; Jacqueline Chen; P M Matthews; Antonio Federico; Nicola De Stefano
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

2.  Early predictors of non-response to interferon in multiple sclerosis.

Authors:  D Horakova; T Kalincik; O Dolezal; J Krasensky; M Vaneckova; Z Seidl; E Havrdova
Journal:  Acta Neurol Scand       Date:  2012-03-16       Impact factor: 3.209

3.  Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

Authors:  R Zivadinov; R A Rudick; R De Masi; D Nasuelli; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

4.  Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study.

Authors:  Robert Zivadinov; Mari Heininen-Brown; Claudiu V Schirda; Guy U Poloni; Niels Bergsland; Christopher R Magnano; Jacqueline Durfee; Cheryl Kennedy; Ellen Carl; Jesper Hagemeier; Ralph H B Benedict; Bianca Weinstock-Guttman; Michael G Dwyer
Journal:  Neuroimage       Date:  2011-07-27       Impact factor: 6.556

5.  Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.

Authors:  R A Rudick; E Fisher; J C Lee; J T Duda; J Simon
Journal:  Mult Scler       Date:  2000-12       Impact factor: 6.312

6.  Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability.

Authors:  Stefan D Roosendaal; Kerstin Bendfeldt; Hugo Vrenken; Chris H Polman; Stefan Borgwardt; Ernst W Radue; Ludwig Kappos; Daniel Pelletier; Stephen L Hauser; Paul M Matthews; Frederik Barkhof; Jeroen J G Geurts
Journal:  Mult Scler       Date:  2011-05-17       Impact factor: 6.312

7.  A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images.

Authors:  Juha Martola; Jakob Bergström; Sten Fredrikson; Leszek Stawiarz; Jan Hillert; Yi Zhang; Olof Flodmark; Anders Lilja; Anders Ekbom; Peter Aspelin; Maria Kristoffersen Wiberg
Journal:  Neuroradiology       Date:  2009-09-23       Impact factor: 2.804

8.  Gray matter atrophy is related to long-term disability in multiple sclerosis.

Authors:  Leonora K Fisniku; Declan T Chard; Jonathan S Jackson; Valerie M Anderson; Daniel R Altmann; Katherine A Miszkiel; Alan J Thompson; David H Miller
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

9.  Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging.

Authors:  Marco Bozzali; Mara Cercignani; Maria Pia Sormani; Giancarlo Comi; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

Review 10.  Gray matter imaging in multiple sclerosis: what have we learned?

Authors:  Hanneke E Hulst; Jeroen J G Geurts
Journal:  BMC Neurol       Date:  2011-12-12       Impact factor: 2.474

View more
  34 in total

Review 1.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

2.  Global and regional annual brain volume loss rates in physiological aging.

Authors:  Sven Schippling; Ann-Christin Ostwaldt; Per Suppa; Lothar Spies; Praveena Manogaran; Carola Gocke; Hans-Jürgen Huppertz; Roland Opfer
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

3.  Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.

Authors:  Athina Papadopoulou; Laura Gaetano; Armanda Pfister; Anna Altermatt; Charidimos Tsagkas; Felix Morency; Alexander U Brandt; Martin Hardmeier; Mallar M Chakravarty; Maxime Descoteaux; Ludwig Kappos; Till Sprenger; Stefano Magon
Journal:  Neurology       Date:  2019-04-10       Impact factor: 9.910

Review 4.  Clinical relevance of brain volume measures in multiple sclerosis.

Authors:  Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

5.  MRI biomarkers of disease progression in multiple sclerosis: old dog, new tricks?

Authors:  Yael Barnett; Justin Y Garber; Michael H Barnett
Journal:  Quant Imaging Med Surg       Date:  2020-02

6.  A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis.

Authors:  Robert Zivadinov; Michael Dwyer; Silva Markovic-Plese; Brooke Hayward; Niels Bergsland; Mari Heininen-Brown; Ellen Carl; Cheryl Kennedy; Fernando Dangond; Bianca Weinstock-Guttman
Journal:  Ther Adv Neurol Disord       Date:  2015-03       Impact factor: 6.570

7.  Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease.

Authors:  Christina J Azevedo; Steven Y Cen; Sankalpa Khadka; Shuang Liu; John Kornak; Yonggang Shi; Ling Zheng; Stephen L Hauser; Daniel Pelletier
Journal:  Ann Neurol       Date:  2018-02-09       Impact factor: 10.422

8.  Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?

Authors:  Dejan Jakimovski; Matthew Topolski; Kana Kimura; Karen Marr; Sirin Gandhi; Deepa P Ramasamy; Niels Bergsland; Jesper Hagemeier; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Clin Auton Res       Date:  2018-08-17       Impact factor: 4.435

9.  Statistical estimation of T1 relaxation times using conventional magnetic resonance imaging.

Authors:  Amanda F Mejia; Elizabeth M Sweeney; Blake Dewey; Govind Nair; Pascal Sati; Colin Shea; Daniel S Reich; Russell T Shinohara
Journal:  Neuroimage       Date:  2015-12-28       Impact factor: 6.556

10.  Power estimation for non-standardized multisite studies.

Authors:  Anisha Keshavan; Friedemann Paul; Mona K Beyer; Alyssa H Zhu; Nico Papinutto; Russell T Shinohara; William Stern; Michael Amann; Rohit Bakshi; Antje Bischof; Alessandro Carriero; Manuel Comabella; Jason C Crane; Sandra D'Alfonso; Philippe Demaerel; Benedicte Dubois; Massimo Filippi; Vinzenz Fleischer; Bertrand Fontaine; Laura Gaetano; An Goris; Christiane Graetz; Adriane Gröger; Sergiu Groppa; David A Hafler; Hanne F Harbo; Bernhard Hemmer; Kesshi Jordan; Ludwig Kappos; Gina Kirkish; Sara Llufriu; Stefano Magon; Filippo Martinelli-Boneschi; Jacob L McCauley; Xavier Montalban; Mark Mühlau; Daniel Pelletier; Pradip M Pattany; Margaret Pericak-Vance; Isabelle Cournu-Rebeix; Maria A Rocca; Alex Rovira; Regina Schlaeger; Albert Saiz; Till Sprenger; Alessandro Stecco; Bernard M J Uitdehaag; Pablo Villoslada; Mike P Wattjes; Howard Weiner; Jens Wuerfel; Claus Zimmer; Frauke Zipp; Stephen L Hauser; Jorge R Oksenberg; Roland G Henry
Journal:  Neuroimage       Date:  2016-04-01       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.